<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35103515</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>5-6</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Analysis of incidence of motor neuron disease in England 1998-2019: use of three linked datasets.</ArticleTitle><Pagination><StartPage>363</StartPage><EndPage>371</EndPage><MedlinePgn>363-371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.2016837</ELocationID><Abstract><AbstractText><i>Objective:</i> This study uses three linked datasets to provide an estimate of incidence of motor neuron disease (MND) in England from 1998 to 2019. Comparison is made to previous British studies. It examines age at diagnosis and ethnicity of those affected.<i>Methods:</i> The literature was searched for studies of MND incidence in Great Britain from 1995 to date. The QResearch and linked Hospital Episode Statistics and Death register databases were searched from 1998 to 2019 for cases of MND, and incidence calculated from 16.8 million adults and 112 million adult years of data.<i>Results:</i> We found 6437 adults with a diagnosis of MND giving an incidence of MND of 5.69/100,000 person years (95% CI 5.51-5.88); 6.57 (6.41-6.99) in men and 4.72 (4.49-4.97) in women when age-standardized to the 2011 UK population. The median age of diagnosis was 72 years. Peak incidence occurred in the 80-84 year age group in men and 75-79 in women. Age-standardized incidence was as high in Bangladeshi, Black Caribbean, Indian, other Asian and Pakistani people as in White people. Black African and Chinese people had a lower incidence.<i>Conclusion:</i> The use of three linked national datasets captured 33% more people than a primary care dataset&#xa0;alone. Patients were older than in previous studies and rates were high in all ethnic groups studied except Black African and Chinese people. We present the highest incidence of MND reported globally in the past 50 years. Methodological differences may in part explain differences with previous reports. The use of national datasets may have captured additional MND patients with serious comorbidities who have not seen a neurologist before death. A limitation of this approach is that unlike population registers, which minimize false positive diagnosis by neurologist review of each patient, we cannot review diagnosis for individuals as data are anonymized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burchardt</LastName><ForeName>Judith M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Xue W</ForeName><Initials>XW</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranger</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-1269-9053</Identifier><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Sheffield, Sheffield, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radunovic</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barts MND Centre, Barts Health NHS Trust, London, England, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coupland</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Nottingham, Nottingham, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hippisley-Cox</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, England.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HIPPISLEY-COX/NOV18/939-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">England</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">QResearch</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35103515</ArticleId><ArticleId IdType="pmc">PMC9344929</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.2016837</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain), National Institute for Health and Care Excellence (Great Britain) . Motor neurone disease: assessment and management. London: National Clinical Guideline Centre; 2016.</Citation></Reference><Reference><Citation>McDermott CJ, Shaw PJ.. Diagnosis and management of motor neurone disease. BMJ. 2008;336:658&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270983</ArticleId><ArticleId IdType="pubmed">18356234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighton DJ, Newton J, Stephenson LJ, Colville S, Davenport R, Gorrie G, CARE-MND Consortium, et al.. Changing epidemiology of motor neurone disease in Scotland. J Neurol. 2019;266:817&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">30805795</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, et al. . Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology. 2007;29:44&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898523</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Logroscino G, Jick SS, Hernan MA.. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16:745&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093130</ArticleId><ArticleId IdType="pubmed">19475756</ArticleId></ArticleIdList></Reference><Reference><Citation>Nageshwaran S, Davies LM, Rafi I, Radunovi A.. Motor neurone disease. BMJ. 2014;349:g4052&#x2013;g4052.</Citation><ArticleIdList><ArticleId IdType="pubmed">25008100</ArticleId></ArticleIdList></Reference><Reference><Citation>Imam I, Ball S, Wright D, Hanemann CO, Zajicek J.. The epidemiology of motor neurone disease in two counties in the southwest of England. J Neurol. 2010;257:977&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20094727</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JD, Gatrell AC, Al-Hamad A, Davies RB, Batterby G.. Geographical epidemiology of residence of patients with motor neuron disease in Lancashire and south Cumbria. J Neurol Neurosurg Psychiatry. 1998;65:842&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170391</ArticleId><ArticleId IdType="pubmed">9854959</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Ossher L, Bredin A, Kulka A, Pearce N, Talbot K, et al. . Motor Neuron Disease Register for England, Wales and Northern Ireland&#x2014;an analysis of incidence in England. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:86&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32940088</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowland A, Opie-Martin S, Scott KM, Jones AR, Mehta PR, Batts CJ, et al. . Predicting the future of ALS: the impact of demographic change and potential new treatments on the prevalence of ALS in the United Kingdom, 2020&#x2013;2116. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:264&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6567553</ArticleId><ArticleId IdType="pubmed">30961394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Stables D, Pringle M.. QRESEARCH: a new general practice database for research. Inform Prim Care. 2004;12:49&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140353</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. 
2011.  UK census data https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/2011censuspopulationestimatesfortheunitedkingdom/2012-12-17.</Citation></Reference><Reference><Citation>US Population Data.  US census. https://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. 2010.</Citation></Reference><Reference><Citation>Forbes RB, Colville S, Parratt J, Swingler RJ.. The incidence of motor nueron disease in Scotland. J Neurol. 2007;254:866&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kab S, Moisan F, Preux PM, Marin B, Elbaz A.. Nationwide incidence of motor neuron disease using the French health insurance information system database. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:426&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">28387141</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle P, Brown A, Beral V, Reeves G, Green J.. Incidence of and risk factors for motor neurone disease in UK women: a prospective study. BMC Neurol. 2012;12:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3512483</ArticleId><ArticleId IdType="pubmed">22559076</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O.. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol. 2000;57:109&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chio' A, Couratier P, Mitchell JD, for EURALS, et al.. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg &amp; Psychiatry. 2008;79:6&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">18079297</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Piccininni M.. Amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference. Neuroepidemiology. 2019;52:93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">30602169</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Piccininni M, Marin B, Nichols E, Abd-Allah F, Abdelalim A, et al. . Global, regional, and national burden of motor neuron diseases 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:1083&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234315</ArticleId><ArticleId IdType="pubmed">30409709</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. 
2020.  UK national life tables. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables.</Citation></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. . Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boum&#xe9;diene F, Logroscino G, Couratier P, Babron M-C, Leutenegger AL, et al. . Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Seals RM, Hansen J, Gredal O, Weisskopf MG.. Age-period-cohort analysis of trends in amyotrophic lateral sclerosis in Denmark, 1970&#x2013;2009. Am J Epidemiol. 2013;178:1265&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792730</ArticleId><ArticleId IdType="pubmed">24064744</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Valdimarsd&#xf3;ttir U, Bellocco R, Ronnevi L-O, Spar&#xe9;n P, Fall K, et al. . Amyotrophic lateral sclerosis in Sweden, 1991&#x2013;2005. Arch Neurol. 2009;66:515&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19364937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Moglia C, Manera U, Canosa A, Cammarosano S, Piemonte and Valle d&#x2019;Aosta Register for ALS (PARALS), et al.. Secular trends of amyotrophic lateral sclerosis: The Piemonte and Valle d'Aosta Register. JAMA Neurol. 2017;74:1097&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710181</ArticleId><ArticleId IdType="pubmed">28692730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. . The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88:557&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28285264</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens DL. Appendix A: Neurology in the United Kingdom&#x2014;numbers of clinical neurologists and trainees. J Neurol Neurosurg &amp; Psychiatry. 1997;63:S67.</Citation></Reference><Reference><Citation>BBC News.  Neurology care 'is lacking' for UK patients. https://wwwbbccouk/news/health-13665523. 2011.</Citation></Reference><Reference><Citation>Nitkunan AL, Reilly MM. Association of British Neurologists UK Neurology Workforce Survey; ACNR 2020.</Citation></Reference><Reference><Citation>Marin B, Fontana A, Arcuti S, Copetti M, Boum&#xe9;diene F, Couratier P, et al. . Age-specific ALS incidence: a dose-response meta-analysis. Eur J Epidemiol. 2018;33:621&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29687175</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh AD, van Eijk RPA, Peters SM, van Es MA, Horemans AMC, van der Kooi AJ, et al. . Incidence, prevalence and geographical clustering of motor neuron disease in the Netherlands. Neurology. 2021;96:e1227&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055340</ArticleId><ArticleId IdType="pubmed">33472922</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Chen L, Wang S, Feng J, Liu L, Liu G, et al. . Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry. 2020;91:520&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">32139654</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chi&#xf2; A, Mitchell D, Swingler RJ, EURALS, et al.. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. . Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Henning F, Heckmann JM, Naidu K, Vlok L, Cross HM, Marin B.. The incidence of motor neuron disease/amyotrophic lateral sclerosis in South Africa: a 4-year prospective study. Eur J Neurol. 2020;28:81&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32888367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O.. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology. 2009;72:1640&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433736</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo L, Lynch C, Hardiman O.. Validating population-based registers for ALS: how accurate is death certification? J Neurol. 2010;257:1235&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20151145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragonese P, Filippini G, Salemi G, Beghi E, Citterio A, D'Alessandro R, et al. . Accuracy of death certificates for amyotrophic lateral sclerosis varies significantly from north to south of Italy: implications for mortality studies. Neuroepidemiology. 2004;23:73&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo K, Tsubaki T.. Changing mortality patterns of motor neuron disease in Japan. J Neurol Sci. 1977;32:411&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">886364</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T, et al. . Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ. 2013;346:f2350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898411</ArticleId><ArticleId IdType="pubmed">23692896</ArticleId></ArticleIdList></Reference><Reference><Citation>Millett ERC, Quint JK, De Stavola BL, Smeeth L, Thomas SL.. Improved incidence estimates from linked vs. stand-alone electronic health records. J Clin Epidemiol. 2016;75:66&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4922622</ArticleId><ArticleId IdType="pubmed">26776084</ArticleId></ArticleIdList></Reference><Reference><Citation>Horrocks S, Wilkinson T, Schnier C, Ly A, Woodfield R, Rannikm&#xe4;e K, et al. . Accuracy of routinely-collected healthcare data for identifying motor neurone disease cases: a systematic review. PLoS One. 2017;12:e0172639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5330471</ArticleId><ArticleId IdType="pubmed">28245254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M-A, Seals RM, Himmerslev L, Gredal O, Hansen J, Weisskopf MG.. Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certificates and hospital discharge data in the Danish population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:224&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675622</ArticleId><ArticleId IdType="pubmed">25946516</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>